Brought to you by 
Ipsen buys Syntaxin for €28mm plus earn-outs
26 Aug 2020
Executive Summary
Ipsen has acquired the rest of Syntaxin Ltd.--a closely held UK-based company focused on botulinum toxin engineering--that it does not already own for €28mm ($37mm) up front, plus earn-outs of up to €130mm for reaching development and commercialization milestones. The majority of the downstream payments are linked to Syntaxin’s most-advanced drug candidate senrebotase (AGN214868).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen buys Syntaxin for €28mm plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice